Sign in Subscribe

article

A collection of 624 issues

Urinary Metabolomics May Improve Survival Prediction Beyond Tumor Stage

Skip to content The CRC Digest ◇ RESEARCH Urinary Metabolomics May Improve Survival Prediction Beyond Tumor Stage Pre-surgery urinary metabolomic profiles improved overall survival prediction performance compared with stage- and age-based models in 76 stage I-IV CRC patients from the ColoCare Study. (Metabolomics) This content is informational only and does not

Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic CRC

Skip to content The CRC Digest ◇ RESEARCH Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic CRC A matching-adjusted indirect comparison evaluated sotorasib combined with panitumumab versus trifluridine/tipiracil plus bevacizumab in chemorefractory metastatic colorectal cancer. (Clinical Colorectal Cancer) This content is informational only

Secondary actionable fusions in MLH1-deficient MSI-H tumors may impact pembrolizumab outcomes

Skip to content The CRC Digest Secondary actionable fusions in MLH1-deficient MSI-H tumors may impact pembrolizumab outcomes A molecular subanalysis of the GAstrointestinal INestable cohort evaluated secondary fusions in MLH1-deficient dMMR/MSI-H gastrointestinal tumors treated with pembrolizumab, finding that these fusions may be enriched in MLH1-deficient colorectal cancer with mitogen-activated

Quality of life analysis from phase II VOLFI trial compares chemotherapy regimens in RAS wild-type metastatic disease

Skip to content The CRC Digest ♥ LIVING WITH CRC Quality of life analysis from phase II VOLFI trial compares chemotherapy regimens in RAS wild-type metastatic disease A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial examined quality of life in patients with RAS wild-type metastatic colorectal cancer

Real-world study of 549 Spanish patients evaluates trifluridine/tipiracil plus bevacizumab

Skip to content The CRC Digest ▸ TREATMENT Real-world study of 549 Spanish patients evaluates trifluridine/tipiracil plus bevacizumab A multicenter study across 19 Spanish hospitals evaluated real-world effectiveness and safety of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer after at least two prior treatment regimens. (ESMO Gastrointestinal

FDA delays decision on zanzalintinib plus Tecentriq for metastatic colorectal cancer until March 2027

Skip to content The CRC Digest ● REGULATORY FDA delays decision on zanzalintinib plus Tecentriq for metastatic colorectal cancer until March 2027 The FDA has extended its approval decision for Exelixis' oral kinase inhibitor zanzalintinib in combination with Roche's Tecentriq to March 2027 while awaiting updated safety and

CRC Research Finding

Skip to content The CRC Digest ● REGULATORY This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

PD-L1 blockade shows activity in MSS rectal cancer when combined with radiation and chemotherapy

Skip to content The CRC Digest ▸ TREATMENT PD-L1 blockade shows activity in MSS rectal cancer when combined with radiation and chemotherapy The PRECAM-R trial demonstrated that short-course radiotherapy may create an immune-priming window in microsatellite-stable tumors, allowing PD-L1 blockade to achieve a 44.8% pathologic complete response rate. (The ASCO

39-year-old proband with Lynch syndrome shows discordant tumor testing

Skip to content The CRC Digest ◇ RESEARCH 39-year-old proband with Lynch syndrome shows discordant tumor testing A 39-year-old man with colorectal cancer and family history fulfilling Amsterdam criteria carried the germline MLH1 c.931A>G variant, with tumors showing MSI-H status despite retained MMR protein expression. (Clinical Case Reports)

Lynch syndrome family shows MSI-H tumors despite preserved MMR protein staining

Skip to content The CRC Digest ◇ RESEARCH Lynch syndrome family shows MSI-H tumors despite preserved MMR protein staining A family carrying germline MLH1 c.931A>G presented with colorectal tumors showing retained mismatch repair protein expression by immunohistochemistry but microsatellite instability-high status on sequencing, highlighting that preserved staining does